TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that the mitochondrial protein Miro1 was elevated in the skeletal muscles of people with type 2 diabetes and impaired muscle response to insulin. Removing Miro1 restored insulin responsiveness in preclinical models, while an exercise trial found lower muscle Miro1 alongside improved insulin sensitivity; whether directly targeting the protein can treat people remains unknown.
Researchers have identified Miro1, a protein on the outer membrane of mitochondria, as a possible contributor to muscle insulin resistance, a central feature of type 2 diabetes. In the study, removing the protein restored insulin responsiveness in preclinical models, while an exercise trial in people with obesity and type 2 diabetes found lower muscle Miro1 levels alongside better insulin sensitivity.
The team examined Miro1 in laboratory cells, preclinical models and people living with type 2 diabetes. They found higher levels of Miro1 in skeletal muscle from people with the disease. The researchers report that excess Miro1 interfered with how muscle responded to insulin, which helps regulate blood sugar.
In preclinical experiments, removing Miro1 restored the muscle’s response to insulin. That result supports a direct role for the protein in the process studied, but it does not show that a Miro1-targeting treatment would be safe or effective in people. The reported restoration was in preclinical models, not a human drug trial.
The human component was a randomized controlled trial involving participants with obesity and type 2 diabetes. Researchers compared aerobic exercise with standard medical care. Muscle Miro1 levels fell in the exercise group, alongside improvements in insulin sensitivity and the muscles’ capacity to produce energy. The study links those changes but does not establish that the drop in Miro1 alone caused the improvements.
How Miro1 Could Affect Muscle Insulin Response
Insulin resistance means the body’s cells respond less effectively to insulin, making blood sugar regulation more difficult. Skeletal muscle is a key site of insulin action, and the study offers a possible molecular explanation for impaired insulin response in that tissue. If further research confirms Miro1’s role, it could give scientists a new target for studying treatment.
The exercise findings also connect a change in muscle biology with a recognized benefit of physical activity: improved insulin sensitivity. Senior author Dr. John P. Kirwan said the results deepen understanding of why exercise is effective and could open a path to treatments that complement it. That is a research possibility, not a therapy currently available to patients.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
From Mitochondria to Diabetes Research
Miro1, short for mitochondrial Rho GTPase 1, is found on the outer membrane of mitochondria, structures inside cells that produce energy. The researchers examined the protein across laboratory and preclinical work as well as a study involving people, to investigate whether findings about muscle function could be relevant to type 2 diabetes.
The work was published in Nature Communications. Kirwan conducted the research while at LSU’s Pennington Biomedical Research Center and has since moved his research program to the University of Oklahoma’s Harold Hamm Diabetes Center. The study’s first author is doctoral candidate Elizabeth Heintz; Christopher Axelrod is a co-corresponding author.
“Insulin resistance in muscle is at the heart of Type 2 diabetes, and its molecular causes have remained frustratingly unclear.”
— Dr. John P. Kirwan, the study’s senior author
What Miro1 Results Do Not Yet Show
The findings do not establish that Miro1 is the sole or primary cause of type 2 diabetes, or that reducing it directly would improve health outcomes in patients. The reported restoration of insulin responsiveness came from preclinical models; the human trial tested exercise, not a drug or other intervention designed specifically to target Miro1.
The source report does not provide the trial’s participant count, the size of the Miro1 reduction, the duration of the intervention or detailed statistical results. It also does not establish how long the changes lasted or whether they apply to people with type 2 diabetes who do not have obesity. Researchers say further work is needed to determine whether directly targeting the protein can lead to safe and effective treatment.
Further Tests of Miro1 as a Treatment Target
Kirwan plans to continue investigating the findings at the Harold Hamm Diabetes Center, combining laboratory experiments with studies involving people. That work is expected to examine the mechanisms linking Miro1, muscle function and insulin resistance, and whether interventions aimed at the protein can affect those processes.
For now, the study identifies a possible biological target rather than a new clinical treatment. Further research will need to test Miro1-directed approaches in people and establish their safety, effectiveness and potential role alongside existing diabetes care.
Key Questions
What is Miro1?
Miro1 is a protein located on the outer membrane of mitochondria, cell structures involved in energy production. The study examined its possible role in how skeletal muscle responds to insulin.
Does the study prove Miro1 causes type 2 diabetes?
No. The researchers found higher muscle Miro1 levels in people with type 2 diabetes and reported that removing the protein restored insulin responsiveness in preclinical models. The results suggest a contribution to muscle insulin resistance, not proof that Miro1 alone causes the disease.
Did exercise lower Miro1 in people?
In a randomized controlled trial involving people with obesity and type 2 diabetes, the aerobic exercise group had lower muscle Miro1 levels alongside improved insulin sensitivity and muscle energy-production capacity. The study does not show that lowering Miro1 alone caused those improvements.
Is there a Miro1-targeting treatment available?
The report describes no approved or tested Miro1-targeting treatment for patients. Researchers say they still need to determine whether directly targeting the protein could produce a safe and effective therapy.
Source: sciencedaily.com
